Mesa RA - Search Results

1

Alternative Outpatient Chemotherapy Scheduling Method to Improve Patient Service Quality and Nurse Satisfaction.

Huang YL, Bryce AH, Culbertson T, Connor SL, Looker SA, Altman KM, Collins JG, Stellner W, McWilliams RR, Moreno-Aspitia A, Ailawadhi S, Mesa RA. Huang YL, et al. Among authors: mesa ra. J Oncol Pract. 2018 Feb;14(2):e82-e91. doi: 10.1200/JOP.2017.025510. Epub 2017 Dec 22. J Oncol Pract. 2018. PMID: 29272201 Free PMC article.

2

Living with Cancer: an Educational Intervention in Cancer Patients Can Improve Patient-Reported Knowledge Deficit.

Padrnos L, Bennett R, Kosiorek H, Dueck AC, Northfelt D, Mikhael J, Tibes R, Khera N, Mesa RA. Padrnos L, et al. Among authors: mesa ra. J Cancer Educ. 2018 Jun;33(3):653-659. doi: 10.1007/s13187-016-1123-1. J Cancer Educ. 2018. PMID: 27730534 Free PMC article.

3

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.

Miller CB, Komrokji RS, Mesa RA, Sun W, Montgomery M, Verstovsek S. Miller CB, et al. Among authors: mesa ra. Clin Lymphoma Myeloma Leuk. 2017 Aug;17(8):479-487. doi: 10.1016/j.clml.2017.05.015. Epub 2017 May 12. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28606598 Free PMC article. Clinical Trial.

4

Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life?

Langlais BT, Geyer H, Scherber R, Mesa RA, Dueck AC. Langlais BT, et al. Among authors: mesa ra. Leuk Lymphoma. 2019 Feb;60(2):402-408. doi: 10.1080/10428194.2018.1480768. Epub 2018 Jul 22. Leuk Lymphoma. 2019. PMID: 30033837 Free PMC article.

5

Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.

Kaufmann SH, Karp JE, Litzow MR, Mesa RA, Hogan W, Steensma DP, Flatten KS, Loegering DA, Schneider PA, Peterson KL, Maurer MJ, Smith BD, Greer J, Chen Y, Reid JM, Ivy SP, Ames MM, Adjei AA, Erlichman C, Karnitz LM. Kaufmann SH, et al. Among authors: mesa ra. Haematologica. 2011 Nov;96(11):1619-26. doi: 10.3324/haematol.2011.049551. Epub 2011 Jul 26. Haematologica. 2011. PMID: 21791475 Free PMC article. Clinical Trial.

6

The future of JAK inhibition in myelofibrosis and beyond.

Mascarenhas JO, Cross NC, Mesa RA. Mascarenhas JO, et al. Among authors: mesa ra. Blood Rev. 2014 Sep;28(5):189-96. doi: 10.1016/j.blre.2014.06.002. Epub 2014 Jun 28. Blood Rev. 2014. PMID: 25043171 Review.

7

Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.

Mesa RA, Scherber RM, Geyer HL. Mesa RA, et al. Leuk Lymphoma. 2015 Jul;56(7):1989-99. doi: 10.3109/10428194.2014.983098. Epub 2015 Mar 17. Leuk Lymphoma. 2015. PMID: 25644746 Review.

8

The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.

Tibes R, Al-Kali A, Oliver GR, Delman DH, Hansen N, Bhagavatula K, Mohan J, Rakhshan F, Wood T, Foran JM, Mesa RA, Bogenberger JM. Tibes R, et al. Among authors: mesa ra. J Hematol Oncol. 2015 Oct 20;8:114. doi: 10.1186/s13045-015-0211-8. J Hematol Oncol. 2015. PMID: 26483188 Free PMC article.

9

Physical Activity as a Nonpharmacological Symptom Management Approach in Myeloproliferative Neoplasms: Recommendations for Future Research.

Eckert R, Huberty J, Gowin K, Mesa R, Marks L. Eckert R, et al. Integr Cancer Ther. 2017 Dec;16(4):439-450. doi: 10.1177/1534735416661417. Epub 2016 Jul 24. Integr Cancer Ther. 2017. PMID: 27458250 Free PMC article. Review.

10

Recent advances in the management of myelofibrosis.

Mesa RA. Mesa RA. Clin Adv Hematol Oncol. 2016 Aug;14(8):597-9. Clin Adv Hematol Oncol. 2016. PMID: 27487103 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

433 results

Search Page

Filters